{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:46:51Z","timestamp":1794433611522,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtho.2026.103688","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:29:38Z","timestamp":1774110578000},"page":"103688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial"],"prefix":"10.1016","volume":"21","author":[{"given":"Benjamin","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Domine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Chiaverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103688_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib2","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1200\/JCO.23.02746","article-title":"Therapy for Stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib3","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.clon.2023.07.012","article-title":"Effect of PD-L1 expression for the PD-1\/L1 inhibitors on non-small cell lung cancer: a meta-analysis based on randomised controlled trials","volume":"35","author":"Xu","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jtho.2026.103688_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/vaccines13020128","article-title":"Emerging immunotherapies for advanced non-small-cell lung cancer","volume":"13","author":"Wolf","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jtho.2026.103688_bib6","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103688_bib7","unstructured":"AstraZeneca. Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/datroway-approved-in-us-for-egfrm-lung-cancer.html. [Accessed 7 November 2025]."},{"key":"10.1016\/j.jtho.2026.103688_bib8","unstructured":"United States Food and Drug Administration. DATROWAY\u00ae (datopotamab deruxtecan-dlnk) for injection, for intravenous use: US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761464s000lbl.pdf. [Accessed 25 June 2025]."},{"key":"10.1016\/j.jtho.2026.103688_bib9","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label Phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.103688_bib13","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103688_bib14","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1158\/1538-7445.AM2023-2932","article-title":"Abstract 2932: Datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1\/PD-L1 inhibitors in TROP2-expressing tumors in mice","volume":"83","author":"Okajima","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.103688_bib15","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib16","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/TCRM.S143939","article-title":"Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis","volume":"13","author":"Cui","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jtho.2026.103688_bib19","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cam4.2104","article-title":"Risk of immune-related pneumonitis for PD1\/PD-L1 inhibitors: systematic review and network meta-analysis","volume":"8","author":"Huang","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2026.103688_bib20","article-title":"118MO trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): interim analysis of a phase Ib study","volume":"24","author":"Italiano","year":"2024","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.jtho.2026.103688_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102572","article-title":"TROP-2 directed antibody-drug conjugates (ADCs): the revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)","volume":"118","author":"Parisi","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2026.103688_bib22","first-page":"756","article-title":"US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan","volume":"33","author":"Rugo","year":"2025","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtho.2026.103688_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2026.103688_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ejhpharm-2021-002803","article-title":"Efficacy and safety of PD-1\/PD-L1 plus CTLA-4 antibodies \u00b1 other therapies in lung cancer: a systematic review and meta-analysis","volume":"30","author":"Shen","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jtho.2026.103688_bib25","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4","article-title":"Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis","volume":"10","author":"Sun","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2026.103688_bib26","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib28","doi-asserted-by":"crossref","first-page":"9222","DOI":"10.1038\/s41598-021-88453-8","article-title":"Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices","volume":"11","author":"Velcheti","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2026.103688_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104164","article-title":"8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab \u00b1 carboplatin in advanced or metastatic non-small cell lung cancer (a\/mNSCLC): results from TROPION-Lung04 (cohorts 2 and 4)","volume":"10","author":"Cuppens","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2026.103688_bib30","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-7149","article-title":"Abstract 7149: The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 normalized membrane ratio","volume":"85","author":"Sung","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.103688_bib31","unstructured":"ClinicalTrials.gov. Study of dato-DXd plus pembrolizumab vs pembrolizumab alone in the first-line treatment of subjects with advanced or metastatic NSCLC without actionable genomic alterations (TROPION-Lung08). https:\/\/clinicaltrials.gov\/study\/NCT05215340. [Accessed 5 September 2025]."},{"key":"10.1016\/j.jtho.2026.103688_bib32","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/fon-2023-0230","article-title":"TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC","volume":"19","author":"Levy","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib33","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1080\/14796694.2024.2409621","article-title":"TROPION-Lung07: phase III study of Dato-DXd + pembrolizumab \u00b1 platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer","volume":"20","author":"Okamoto","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2026.103688_bib34","unstructured":"ClinicalTrials.gov. Datopotamab deruxtecan (Dato-DXd) and pembrolizumab with or without platinum chemotherapy in 1L non-small cell lung cancer (TROPION-Lung07). https:\/\/clinicaltrials.gov\/study\/NCT05555732. [Accessed 20 September 2025]."},{"key":"10.1016\/j.jtho.2026.103688_bib36","unstructured":"ClinicalTrials.gov. Phase III, open-label, study of first-line dato-DXd in combination with rilvegostomig for advanced non-squamous NSCLC with high PD-L1 expression (TC \u2265 50%) and without actionable genomic alterations (TROPION-Lung10). https:\/\/clinicaltrials.gov\/study\/NCT06357533. [Accessed 3 November 2025]."}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:39:46Z","timestamp":1783071586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556086426001413"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103688","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103688"}}